Sigyn’s Jeremy Farrell is preparing to issue more shares even as some companies are shying away from tapping equity amid rising stock market volatility. Sigyn Therapeutic’s new CFO is betting the medical technology company can overcome stock market volatility to unlock a longer-term financing runway through a shelf registration and an uplisting to the Nasdaq exchange […]

Need to Know: Social media can be a powerful tool to directly advertise ongoing clinical trials to target patients, but such an unregulated space increases the risk of companies being exposed of negative or untrue comments. While having an inhouse press team allows a pharma company to have a dedicated crew for its communication plans, […]

Athira Pharma has dosed the first subject in the Phase I clinical trial of its treatment candidate, ATH-1020, to potentially treat neuropsychiatric conditions. An orally available, brain-penetrant small molecule, ATH-1020 is created to boost HGF/MET system. The first-in-human placebo-controlled, randomised, double-blind, two-part trial will assess the safety, tolerability and pharmacokinetics of single and multiple ascending doses of […]